Symbols / PEN Stock $333.58 +0.41% Penumbra, Inc.

Healthcare • Medical Devices • United States • NYQ
PEN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Stock Fundamentals
Scroll to Statements
Market Cap 13.09B Enterprise Value 12.71B Income 177.69M Sales 1.40B Book/sh 36.39 Cash/sh 13.88
Dividend Yield — Payout 0.00% Employees 4700 IPO — P/E 73.80 Forward P/E 52.30
PEG 0.74 P/S 9.33 P/B 9.17 P/C — EV/EBITDA 61.55 EV/Sales 9.06
Quick Ratio 4.01 Current Ratio 6.64 Debt/Eq 15.39 LT Debt/Eq — EPS (ttm) 4.52 EPS next Y 6.38
EPS Growth 38.30% Revenue Growth 22.10% Earnings 2026-04-24 ROA 7.04% ROE 13.78% ROIC —
Gross Margin 67.14% Oper. Margin 15.37% Profit Margin 12.66% Shs Outstand 39.24M Shs Float 38.05M Short Float 8.40%
Short Ratio 3.75 Short Interest — 52W High 362.41 52W Low 221.26 Beta 0.84 Avg Volume 719.29K
Volume 371.41K Target Price $365.79 Recom Hold Prev Close $332.21 Price $333.57 Change 0.41%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$365.79
Mean price target
2. Current target
$333.58
Latest analyst target
3. DCF / Fair value
$42.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$333.58
Low
$326.00
High
$374.00
Mean
$365.79

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-26 main Evercore ISI Group Outperform → Outperform $360
2026-01-20 down RBC Capital Outperform → Sector Perform $374
2026-01-20 down Canaccord Genuity Buy → Hold $374
2026-01-16 down Jefferies Buy → Hold $374
2026-01-16 down Needham Buy → Hold —
2026-01-16 down Citigroup Buy → Neutral $374
2026-01-16 down Leerink Partners Outperform → Market Perform $374
2026-01-16 down Baird Outperform → Neutral $374
2026-01-16 down BTIG Buy → Neutral $349
2026-01-16 down Truist Securities Buy → Hold $374
2026-01-15 down Wells Fargo Overweight → Equal-Weight $374
2026-01-15 down William Blair Outperform → Market Perform —
2026-01-05 main B of A Securities Buy → Buy $370
2025-12-18 main Truist Securities Buy → Buy $370
2025-12-18 up JP Morgan Neutral → Overweight $370
2025-12-17 main Canaccord Genuity Buy → Buy $359
2025-12-17 main Needham Buy → Buy $388
2025-12-11 up Citigroup Neutral → Buy $350
2025-11-06 main JP Morgan Neutral → Neutral $275
2025-11-06 main Canaccord Genuity Buy → Buy $355
News
RSS: Latest PEN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 GREWAL HARPREET SINGH Director — 100 $328.22 $32,822
2026-03-02 YUEN MAGGIE S. Chief Financial Officer — 2,432 $342.30 $832,474
2026-02-17 ROBERTS JOHANNA General Counsel — 5,260 $0.00 $0
2026-02-17 YUEN MAGGIE S. Chief Financial Officer — 5,260 $0.00 $0
2026-02-17 SHIU LAMBERT Officer — 4,600 $0.00 $0
2026-02-17 NARAYAN SHRUTHI President — 5,260 $0.00 $0
2026-02-13 BOSE ARANI Director — 589 $0.00 $0
2026-02-13 O'ROURKE BRIDGET A Director — 589 $0.00 $0
2026-02-13 LEEDS JANET Director — 589 $0.00 $0
2026-02-13 SARNA SURBHI Director — 589 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,403.66
+17.50%
1,194.62
+12.86%
1,058.52
+24.95%
847.13
Operating Revenue
1,403.66
+17.50%
1,194.62
+12.86%
1,058.52
+24.95%
847.13
Cost Of Revenue
461.23
+4.92%
439.62
+16.96%
375.88
+20.50%
311.93
Reconciled Cost Of Revenue
461.23
+4.92%
439.62
+16.96%
375.88
+20.50%
311.93
Gross Profit
942.44
+24.83%
755.00
+10.60%
682.64
+27.55%
535.21
Operating Expense
753.19
+12.62%
668.77
+13.18%
590.88
+11.67%
529.12
Research And Development
89.77
-5.29%
94.78
+12.27%
84.42
+6.32%
79.41
Selling General And Administration
663.42
+15.58%
573.99
+13.33%
506.45
+12.62%
449.72
Total Expenses
1,214.42
+9.57%
1,108.39
+14.65%
966.76
+14.95%
841.05
Operating Income
189.25
+119.49%
86.22
-6.04%
91.77
+1408.81%
6.08
Total Operating Income As Reported
189.25
+1939.54%
9.28
-87.38%
73.55
+1109.32%
6.08
EBITDA
223.91
+386.87%
45.99
-57.67%
108.65
+262.61%
29.96
Normalized EBITDA
223.91
+82.14%
122.93
-3.10%
126.86
+323.41%
29.96
Reconciled Depreciation
17.47
-26.29%
23.70
-13.04%
27.26
+12.07%
24.32
EBIT
206.44
+826.26%
22.29
-72.62%
81.39
+1342.81%
5.64
Total Unusual Items
0.00
+100.00%
-76.94
-322.43%
-18.21
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-76.94
-322.43%
-18.21
0.00
Special Income Charges
0.00
+100.00%
-76.94
-322.43%
-18.21
0.00
Other Special Charges
—
—
18.21
—
Impairment Of Capital Assets
—
76.94
0.00
0.00
Write Off
0.00
—
—
—
Net Income
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Pretax Income
205.12
+882.92%
20.87
-73.80%
79.65
+1946.51%
3.89
Net Non Operating Interest Income Expense
14.98
+22.09%
12.27
+141.29%
5.09
+3612.41%
0.14
Interest Expense Non Operating
1.31
-7.55%
1.42
-18.46%
1.74
-0.57%
1.75
Net Interest Income
14.98
+22.09%
12.27
+141.29%
5.09
+3612.41%
0.14
Interest Expense
1.31
-7.55%
1.42
-18.46%
1.74
-0.57%
1.75
Interest Income Non Operating
16.29
+19.02%
13.69
+100.59%
6.83
+261.88%
1.89
Interest Income
16.29
+19.02%
13.69
+100.59%
6.83
+261.88%
1.89
Other Income Expense
0.89
+101.15%
-77.63
-351.27%
-17.20
-639.24%
-2.33
Other Non Operating Income Expenses
0.89
+230.94%
-0.68
-167.32%
1.01
+143.53%
-2.33
Tax Provision
27.44
+300.15%
6.86
+160.66%
-11.30
-291.79%
5.89
Tax Rate For Calcs
0.00
-59.27%
0.00
+56.67%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-25.31
-561.80%
-3.83
0.00
Net Income Including Noncontrolling Interests
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Net Income From Continuing Operation Net Minority Interest
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Net Income From Continuing And Discontinued Operation
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Net Income Continuous Operations
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Minority Interests
—
—
0.00
0.00
Normalized Income
177.69
+170.69%
65.64
-37.69%
105.34
+5361.93%
-2.00
Net Income Common Stockholders
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Diluted EPS
4.52
+1155.56%
0.36
-84.48%
2.32
+4740.00%
-0.05
Basic EPS
4.57
+1169.44%
0.36
-84.81%
2.37
+4840.00%
-0.05
Basic Average Shares
38.92
+0.74%
38.63
+0.61%
38.40
+1.48%
37.84
Diluted Average Shares
39.29
+0.06%
39.27
+0.13%
39.22
+3.63%
37.84
Diluted NI Availto Com Stockholders
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Line Item Trend 2023-12-31
Total Assets
1,556.31
Current Assets
915.40
Cash Cash Equivalents And Short Term Investments
289.19
Cash And Cash Equivalents
167.49
Other Short Term Investments
121.70
Receivables
201.77
Accounts Receivable
201.77
Gross Accounts Receivable
204.94
Allowance For Doubtful Accounts Receivable
-3.17
Inventory
388.02
Raw Materials
119.51
Work In Process
34.49
Finished Goods
234.02
Prepaid Assets
—
Other Current Assets
36.42
Total Non Current Assets
640.90
Net PPE
280.50
Gross PPE
332.25
Accumulated Depreciation
-51.75
Properties
0.00
Machinery Furniture Equipment
79.63
Construction In Progress
3.54
Other Properties
219.85
Leases
29.24
Goodwill And Other Intangible Assets
249.37
Goodwill
166.27
Other Intangible Assets
83.09
Non Current Deferred Assets
85.16
Non Current Deferred Taxes Assets
85.16
Other Non Current Assets
25.88
Total Liabilities Net Minority Interest
377.36
Current Liabilities
151.14
Payables And Accrued Expenses
130.72
Payables
27.16
Accounts Payable
27.16
Current Accrued Expenses
103.57
Current Debt And Capital Lease Obligation
13.43
Current Capital Lease Obligation
13.43
Current Deferred Liabilities
6.99
Current Deferred Revenue
6.99
Total Non Current Liabilities Net Minority Interest
226.22
Long Term Debt And Capital Lease Obligation
220.91
Long Term Capital Lease Obligation
220.91
Other Non Current Liabilities
5.31
Stockholders Equity
1,178.94
Common Stock Equity
1,178.94
Capital Stock
0.04
Common Stock
0.04
Preferred Stock
0.00
Share Issued
38.68
Ordinary Shares Number
38.68
Treasury Shares Number
0.00
Additional Paid In Capital
1,047.20
Retained Earnings
134.86
Gains Losses Not Affecting Retained Earnings
-3.15
Minority Interest
—
Other Equity Adjustments
-3.15
Total Equity Gross Minority Interest
1,178.94
Total Capitalization
1,178.94
Working Capital
764.26
Invested Capital
1,178.94
Total Debt
234.34
Capital Lease Obligations
234.34
Net Tangible Assets
929.58
Tangible Book Value
929.58
Current Provisions
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
238.66
+41.66%
168.48
+73.10%
97.33
+274.87%
-55.66
Cash Flow From Continuing Operating Activities
238.66
+41.66%
168.48
+73.10%
97.33
+274.87%
-55.66
Net Income From Continuing Operations
177.69
+1168.11%
14.01
-84.59%
90.95
+4643.16%
-2.00
Depreciation Amortization Depletion
17.47
-26.29%
23.70
-13.04%
27.26
+12.07%
24.32
Depreciation And Amortization
17.47
-26.29%
23.70
-13.04%
27.26
+12.07%
24.32
Other Non Cash Items
0.20
-95.03%
4.12
-79.95%
20.55
+1513.27%
1.27
Stock Based Compensation
59.21
+28.27%
46.16
-8.62%
50.52
+35.15%
37.38
Asset Impairment Charge
5.77
-95.22%
120.60
+1845.81%
6.20
+79.91%
3.44
Deferred Tax
21.03
+228.73%
-16.34
+14.28%
-19.06
-1407.34%
1.46
Deferred Income Tax
21.03
+228.73%
-16.34
+14.28%
-19.06
-1407.34%
1.46
Change In Working Capital
-42.72
-79.63%
-23.78
+69.93%
-79.08
+34.93%
-121.53
Change In Receivables
-19.51
-173.37%
26.60
+10098.87%
-0.27
+99.62%
-69.86
Changes In Account Receivables
-19.51
-173.37%
26.60
+10098.87%
-0.27
+99.62%
-69.86
Change In Inventory
-26.48
+59.67%
-65.66
+3.03%
-67.71
+9.27%
-74.63
Change In Prepaid Assets
-12.70
-330.70%
-2.95
+84.41%
-18.91
-1428.62%
-1.24
Change In Payables And Accrued Expense
15.98
-12.35%
18.23
+149.10%
7.32
-69.42%
23.93
Change In Accrued Expense
12.91
-8.16%
14.06
+125.96%
6.22
-40.99%
10.54
Change In Payable
3.07
-26.49%
4.17
+280.31%
1.10
-91.80%
13.38
Change In Account Payable
3.07
-26.49%
4.17
+280.31%
1.10
-91.80%
13.38
Change In Other Working Capital
—
—
0.48
+83.65%
0.26
Investing Cash Flow
-404.59
-621.22%
77.62
+582.86%
-16.08
-129.34%
54.79
Cash Flow From Continuing Investing Activities
-404.59
-621.22%
77.62
+582.86%
-16.08
-129.34%
54.79
Net PPE Purchase And Sale
-63.73
-200.86%
-21.18
-39.24%
-15.21
+21.17%
-19.30
Purchase Of PPE
-63.73
-200.86%
-21.18
-39.24%
-15.21
+21.17%
-19.30
Capital Expenditure
-63.73
-200.86%
-21.18
-39.24%
-15.21
+21.17%
-19.30
Net Investment Purchase And Sale
-340.86
-448.86%
97.71
+15532.96%
0.62
-99.16%
74.09
Purchase Of Investment
-355.74
-980.94%
-32.91
+59.84%
-81.94
0.00
Sale Of Investment
14.88
-88.61%
130.62
+58.20%
82.56
+11.44%
74.09
Net Business Purchase And Sale
—
—
-0.99
0.00
Purchase Of Business
—
—
-0.99
0.00
Net Other Investing Changes
—
1.10
+173.92%
-1.49
—
Financing Cash Flow
26.53
+130.49%
-87.01
-636.97%
16.20
+39.42%
11.62
Cash Flow From Continuing Financing Activities
26.53
+130.49%
-87.01
-636.97%
16.20
+39.42%
11.62
Net Issuance Payments Of Debt
-2.48
-9.18%
-2.28
-14.89%
-1.98
-13.14%
-1.75
Repayment Of Debt
-2.48
-9.18%
-2.28
-14.89%
-1.98
-13.14%
-1.75
Long Term Debt Payments
-2.48
-9.18%
-2.28
-14.89%
-1.98
-13.14%
-1.75
Net Long Term Debt Issuance
-2.48
-9.18%
-2.28
-14.89%
-1.98
-13.14%
-1.75
Net Common Stock Issuance
0.00
+100.00%
-100.39
0.00
0.00
Common Stock Payments
0.00
+100.00%
-100.39
0.00
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-100.39
0.00
0.00
Proceeds From Stock Option Exercised
31.82
+85.27%
17.17
-15.87%
20.41
-5.28%
21.55
Net Other Financing Charges
-2.80
-84.71%
-1.52
+31.94%
-2.23
+72.75%
-8.18
Changes In Cash
-139.40
-187.62%
159.10
+63.25%
97.46
+806.52%
10.75
Effect Of Exchange Rate Changes
1.89
+186.57%
-2.18
-1398.21%
0.17
+161.76%
-0.27
Beginning Cash Position
324.40
+93.69%
167.49
+139.75%
69.86
+17.65%
59.38
End Cash Position
186.90
-42.39%
324.40
+93.69%
167.49
+139.75%
69.86
Free Cash Flow
174.93
+18.76%
147.30
+79.37%
82.12
+209.55%
-74.96
Income Tax Paid Supplemental Data
—
20.67
+215.30%
6.56
+124.63%
2.92
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
Sale Of Business
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category